Litigation Details for Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals of New York, LLC (D. Del. 2018)
✉ Email this page to a colleague
Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals of New York, LLC (D. Del. 2018)
Small Molecule Drugs cited in Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals of New York, LLC
Biologic Drugs cited in Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals of New York, LLC
The biologic drugs covered by the patents cited in this case are ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , ⤷ Sign Up , and ⤷ Sign Up .
Details for Par Pharmaceutical, Inc. v. Amneal Pharmaceuticals of New York, LLC (D. Del. 2018)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2018-12-19 | 1 | the ‘209 Patent”), 9,744,239 (“the ‘239 Patent”), 9,750,785 (“the ‘785 Patent”) and 9,937,223 (“the ‘223… United States Patent Nos. 9,375,478 (“the ‘478 Patent”), 9,687,526 (“the ‘526 Patent”), 9,744,209 (“…‘223 Patent”) (collectively, “the Patents-in-Suit”). This action is based upon the Patent Laws of the… The Patents-in-Suit 14. On June 28, 2016, the United States Patent and Trademark…copy of the ‘478 Patent is attached as Exhibit A. Par Pharmaceutical owns the ‘478 Patent. 15. | External link to document | |
2020-07-09 | 156 | Exhibit 1 | 14. United States Patent No. 9,375,478 (“the ’478 patent”) is titled “Vasopressin Formulations…face of United States Patent No. 9,744,209 (“the ’209 patent”), the ’209 patent issued on August 29,…face of United States Patent No. 9,750,785 (“the ’785 patent”), the ’785 patent issued on September …in the ’239 patent. See, e.g., id. 162. The ’223 patent, like the ’239 patent, claims a vasopressin…Invalidity of the ’785 patent) Each of the claims of the ’785 patent are invalid for failure | External link to document |
2020-07-09 | 157 | Redacted Document | . 14. United States Patent No. 9,375,478 (“the ’478 patent”) is titled “Vasopressin Formulations…face of United States Patent No. 9,744,209 (“the ’209 patent”), the ’209 patent issued on August 29, …face of United States Patent No. 9,750,785 (“the ’785 patent”), the ’785 patent issued on September 5… in the ’239 patent. See, e.g., id. 162. The ’223 patent, like the ’239 patent, claims a vasopressin…(Invalidity of the ’785 patent) Each of the claims of the ’785 patent are invalid for failure | External link to document |
2020-07-09 | 158 | complaint alleges infringement of U.S. Patent Nos. 5,665,772; 6,004,973; and 6,455,518 because we submitted…complaint alleges infringement of U.S. Patent Nos. 5,665,772; 6,004,973; and 6,455,518 because we submitted…obtain new patents on drugs for which patent protection is about to expire; • filing patent applications…to each patent that: • the required patent information has not been filed; • the listed patent has expired…infringed U.S. Patent Nos. 6,024,981 (the “’981 patent”) and 6,221,392 (the “’392 patent”) by submitting | External link to document | |
2020-07-09 | 160 | nonstatutory double patenting as being unpatentable over claims 1-11 of U.S. Patent No. 9,375,478 in view of in… they are not patentably distinct from each other. Claim 1 of U.S. Patent No. 9,375,478 recites a method… 2 of U.S. Patent No. 9,375,478, respectively. With respect to claims 26 and 27, the patent at claim 1…issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration…issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration | External link to document | |
2020-07-09 | 161 | Exhibit 2 | alleges infringement of United States Patent Nos. 9,375,478 (“the ’478 Ppatent”); 9,687,526 (“the ’526…that according to the face of United States Patent No. 9,375,478, the ’478 Ppatent issued on June 28, 2016…declaring that the claims of United States Patent Nos. 9,375,478 (“the ’478 Ppatent”); 9,687,526 (“the ’…BACKGROUND 12. United States Patent No. 9,375,478 is titled “Vasopressin Formulations for … OF THE ’478 PATENT, THE ’526 PATENT, THE ’209 PATENT, THE ’239 PATENT, THE ’785 PATENT, AND THE | External link to document |
2020-07-09 | 162 | Redacted Document | United States Patent Nos. 9,375,478 (“the ’478 patent”); 9,687,526 (“the ’526 patent”); 9,744,209 (… United States Patent Nos. 9,375,478 (“the ’478 patent”); 9,687,526 (“the ’526 patent”); 9,744,209 (“…according to the face of United States Patent No. 9,375,478, the ’478 patent issued on June 28, 2016, is titled…BACKGROUND 12. United States Patent No. 9,375,478 is titled “Vasopressin Formulations for … (“the ’209 patent”); 9,750,785 (“the ’785 patent”); and 9,937,223 (“the ’223 patent”) (collectively, | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |